3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Magnetic Resonance Spectroscopy
13
Temozolomide
11
Specimen Handling
8
X-Rays
7
Biopsy
7
Nuclear Medicine Department, Hospital
6
Radiation
5
Phantoms, Imaging
5
erdafitinib
4
ulixertinib
3
trametinib
3
larotrectinib
3
dabrafenib
3
Radiotherapy
3
tipifarnib
2
selpercatinib
2
palbociclib
2
olaparib
2
ivosidenib
2
ensartinib
2
binimetinib
2
D2C7-(scdsFv)-PE38KDEL
2
vorasidenib
1
veliparib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tazemetostat
1
selinexor
1
sapanisertib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioma
×
durvalumab
×
30 days
×
Clear all
No trials found.